Lilly, a pharmaceutical company, is deploying the world’s largest AI factory for drug discovery using NVIDIA Blackwell-based DGX SuperPOD, equipped with over 1,000 NVIDIA Blackwell Ultra GPUs. The AI factory will compress drug discovery timelines and accelerate breakthroughs in genomics, personalized medicine, and molecular design at an industrial scale.

The AI factory will train large-scale biomedical foundation and frontier models for drug discovery and development. Models will be accessible on Lilly TuneLab, an AI platform offering access to drug discovery models built on $1 billion worth of Lilly’s proprietary data. The platform also includes NVIDIA Clara open foundation models for healthcare and life sciences.

Lilly’s AI factory is powered by NVIDIA’s full-stack AI factory architecture, offering accelerated computing, NVIDIA Spectrum-X Ethernet networking, and optimized AI software. The NVIDIA Mission Control software enables Lilly to efficiently manage its DGX SuperPOD, orchestrate workloads, monitor performance, and automate AI operations across more than 1,000 GPUs.

Using the NVIDIA BioNeMo platform, Lilly can train AI models to generate and test new antibodies, nanobodies, and molecules with increased accuracy and speed. The AI factory will also assist in discovering new biomarkers, designing gene therapies, and accelerating clinical trials through large language models and the MONAI framework for imaging-based research in precision medicine.

The AI factory will enhance Lilly’s capacity to manufacture high-demand medications and strengthen supply chain reliability by utilizing technologies like NVIDIA Omniverse and RTX PRO Servers to create digital twins of manufacturing lines. These digital twins will optimize production safety, accelerate quality assurance, and streamline biomanufacturing operations.

The collaboration with NVIDIA positions Lilly as an AI-native leader in the pharmaceutical industry, fueling economic growth and creating high-wage jobs. Lilly’s commitment to expanding its U.S. manufacturing and R&D footprint includes initiatives like the Lilly Medicine Foundry in Indiana, poised to create thousands of jobs and drive innovation in advanced manufacturing and regulated industries.

Read more at NVIDIA: Lilly Deploys World’s Largest, Most Powerful AI Factory for Drug Discovery Using NVIDIA Blackwell-Based DGX SuperPOD